Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Santé Ventures
Biotech
How Boston biotechs cope with shallower pool of seed funding
With the average seed round dropping 40% in the first half of the year, CEOs and investors told Fierce where they think the industry is heading.
Will Maddox
Oct 16, 2026 7:00am
Newly formed Jaguar acquires Afib device assets from J&J
Sep 15, 2026 11:11am
Santé Ventures closes $330M fund for biotech, medtech and more
Feb 2, 2026 8:15am
After 'complete standstill,' biotech market reaches new normal
Aug 20, 2025 11:04am
Stroke device maker RapidPulse spins out of Syntheon incubator
Jun 28, 2021 6:50am
Nirogy emerges with $16.5M to target metabolite transporters
Jan 26, 2021 8:00am